Company Overview and News


Add MACK
to your dashboard

Headline News

Mack Trading Co reports standalone net profit of Rs 0.01 crore in the June 2016 quarter

2016-08-13 indiainfoline
Mack Trading Co reports standalone net profit of Rs 0.01 crore in the June 2016 quarter

Columbia Funds Series Trust II Form N-Q

2015-12-29 sec.gov
      OMB APPROVAL     OMB Number: 3235-0578     Expires: January 31, 2016   UNITED STATES Estimated average burden hours per response. . . . 10.5   SECURITIES AND EXCHANGE COMMISSION     Washington, D.C. 20549     FORM N-Q   QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY   Investment Company Act file number 811-21852   Columbia Funds Series Trust II (Exact name of registrant as specified in charter)   50606 Ameriprise Financial Center Minneapolis, MN   5547

COLUMBIA FUNDS SERIES TRUST Form N-Q

2015-12-29 sec.gov
      OMB APPROVAL     OMB Number: 3235-0578     Expires: January 31, 2016   UNITED STATES Estimated average burden hours per response . . . . . . . . . . 10.5   SECURITIES AND EXCHANGE COMMISSION     Washington, D.C. 20549     FORM N-Q   QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY   Investment Company Act file number 811-09645   Columbia Funds Series Trust (Exact name of registrant as specified in charter)   50606 Ameriprise Financial Center Minneapolis,

Premarket Biotech Digest: Arrowhead's Potential, KaloBios Delisting, BiondVax Patent

2015-12-28 seekingalpha
Arrowhead could take off in 2016.KaloBios will be delisted from the NASDAQ this week.Biondvax has been granted a patent for its flu vaccine.

Premarket Biotech Digest: Celldex's Catalyst, Shire-Baxalta Deal, PSivida Surges

2015-12-24 seekingalpha
Celldex is set up nicely for a bounce-back in 2016.Shire and Baxalta are close to completing a deal says Reuters.PSivida surges on positive data from Phase III trial.

Do Hedge Funds Love Merrimack Pharmaceuticals Inc (MACK)?

2015-12-13 insidermonkey
Hedge funds are not perfect. They have their bad picks just like everyone else. Micron, a stock hedge funds have loved, lost 50% during the last 12 months...

Do Hedge Funds Love Ollie’s Bargain Outlet Holdings Inc (OLLI)?

2015-12-13 insidermonkey
It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the...

Hercules Technology Growth Capital Form N-2/A

2015-12-12 sec.gov
Amendment No 1. to Form N-2 Table of Contents Index to Financial Statements As filed with the Securities and Exchange Commission on June 8, 2015 Securities Act File No. 333-203511     U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     FORM N-2 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 (Check appropriate box or boxes)     Pre-Effective Amendment No. 1 Post-Effective Amendment No.

SEASONS SERIES TRUST Form N-CSRS

2015-12-09 sec.gov
  UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM N-CSR   CERTIFIED SHAREHOLDER REPORT OF REGISTERED MANAGEMENT INVESTMENT COMPANIES   Investment Company Act file number 811-07725   SEASONS SERIES TRUST (Exact name of registrant as specified in charter)   1999 Avenue of the Stars, 27th Floor, Los Angeles, CA   90067-6022 (Address of principal executive offices)   (Zip code)   John T.

Merrimack Pharmaceuticals, Inc. – Value Analysis (NASDAQ:MACK) : November 30, 2015

2015-12-01 capitalcube
Click here to see latest analysisCapitalcube gives Merrimack Pharmaceuticals, Inc. a score of 38.Our analysis is based on comparing Merrimack Pharmaceuticals, Inc. with the following peers – Celgene Corporation, Sanofi Sponsored ADR, Dyax Corp., AVEO Pharmaceuticals, Inc., Geron Corporation, Clovis Oncology, Inc., Cerulean Pharma, Inc., Immunomedics, Inc., Synta Pharmaceuticals Corp. and BioTime, Inc.

Merrimack Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : November 30, 2015

2015-12-01 capitalcube
Click here to see latest analysis*Disclaimer : This is as of previous day’s closing price.Technical IndicatorsBelow is a quick look at 5 technical indicators for Merrimack Pharmaceuticals, Inc.. More studies are available on the Technical Chart.IndicatorSignalClosing Price above/below 50 Day Moving AverageBullishClosing Price above/below 200 Day Moving AverageBearish50 Day Moving Average above/below 200 Day Moving …

VANGUARD VALLEY FORGE FUNDS Form N-Q

2015-12-01 sec.gov
valleyforge_final.htm - Generated by SEC Publisher for SEC Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT COMPANY   Investment Company Act file number:   811-58431   Name of Registrant:   Vanguard Valley Forge Funds   Address of Registrant: P.O. Box 2600 Valley Forge, PA 19482   Name and address of agent for service: Heidi Stam, Esquire P.

VANGUARD INSTITUTIONAL INDEX FUNDS Form N-Q

2015-12-01 sec.gov
institutionalindex_final.htm - Generated by SEC Publisher for SEC Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT COMPANY   Investment Company Act file number:    811-06093   Name of Registrant:   Vanguard Institutional Index Funds   Address of Registrant: P.O. Box 2600 Valley Forge, PA 19482   Name and address of agent for service: Heidi Stam, Esquire P.

VANGUARD INDEX FUNDS Form N-Q

2015-12-01 sec.gov
index_final.htm - Generated by SEC Publisher for SEC Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT COMPANY   Investment Company Act file number:   811-02652   Name of Registrant:   Vanguard Index Funds   Address of Registrant: P.O. Box 2600 Valley Forge, PA 19482   Name and address of agent for service: Heidi Stam, Esquire P.

Vanguard Montgomery Funds Form EX-99.CERT

2015-12-01 sec.gov
certifications.htm - Generated by SEC Publisher for SEC Filing   CERTIFICATIONS   I, F. William McNabb III, certify that:   1. I have reviewed this report on Form N-Q of Vanguard Montgomery Funds;   2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Stock Research Report

Merrimack Pharmaceuticals is a biopharmaceutical company based in Cambridge, Massachusetts that is outthinking cancer to ensure that patients and their families live fulfilling lives. Merrimack's mission is to transform cancer care through the smart design and development of targeted solutions based on a deep understanding of cancer pathways and biological markers. All its product candidates, including three in clinical studies and several others in preclinical development, fit into its strategy of (1) understanding the biological problems the company is trying to solve, (2) designing specific solutions and (3) developing those solutions for biomarker-selected patients. This three-pronged strategy seeks to ensure optimal patient outcomes.

On April 3, 2017, Merrimack Pharmaceuticals announced that the company commenced operating as a refocused research and clinical development company in connection with the completion of Merrimack's previously announced transaction, or the asset sa...

Click for full article